Finerenone cleared another major efficacy bar in chronic kidney disease without diabetes after results from the Phase III FIND-CKD trial showed slower kidney function decline and reduced cardiovascular risk. The study evaluated the non-steroidal mineralocorticoid receptor antagonist in adults with CKD and no diabetes, and is described as the largest trial of its kind in this population. The key readouts were framed around slowing deterioration in renal function and lowering cardiovascular events, reinforcing finerenone’s role in cardio-renal risk management beyond diabetic CKD. A defining factor for clinicians and payers will be how the magnitude of benefit compares with existing standard-of-care approaches in non-diabetic patients. The results add weight to mineralocorticoid receptor blockade as a cross-spectrum kidney strategy, potentially affecting treatment guidelines for CKD subgroups that historically have had fewer disease-modifying options. Next steps will hinge on regulatory discussions and any post-hoc analyses planned by the sponsors to identify which patient characteristics predict the strongest benefit.